Baker Bros. Advisors Adds $116M in GRAIL, Inc. ($GRAL)
Key Points
- Baker Bros. Advisors changed its GRAIL, Inc. ($GRAL) stake by 93.2% last quarter, boosting to 4,028,614 shares worth $241.11 million.
- Wall Street's consensus rating on $GRAL is Buy and an average price target of $66.00.
- $GRAL last traded around $59.85.
Baker Bros. Advisors increased its position in GRAIL, Inc. ($GRAL) by 93.2% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,028,614 shares of GRAIL, Inc. after buying 1,943,281 shares during the quarter. Baker Bros. Advisors's holdings in GRAIL, Inc. were worth $241.11 million as of its most recent filing.
GRAIL, Inc. ($GRAL) Stock
GRAIL, Inc. Earnings
Analysts Set New Price Targets
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.